Under Burn Care

Hemodynamic Consequences of Acute Burns

George C. Kramer writes:

Hemodynamic consequences of acute burns

The cause of reduced cardiac output during the resuscitative phase of burn injury has been the subject of considerable debate. There is an immediate depression of cardiac output before any detectable reduction in plasma volume. The rapidity of the response may result from impaired electrical activity of cardiac nerves and muscle and increased afterload due to vasoconstriction. Soon after injury developing hypovolemia and reduced venous return undeniably contribute to the reduced cardiac output.  The subsequent persistence of reduced CO after apparently adequate fluid therapy, as evidenced by restoration of arterial blood pressure and urinary output, has been attributed to circulating myocardial depressant factor(s), which possibly originates from the burn wound.  It was concluded that the depression of CO resulted not only from decreased blood volume and venous return, but also from and increased SVR and from the presence of a circulating myocardial depressant substance. After the resuscitation phase of burn shock, patients can have supranormal CO.  This is associated with a hypermetabolic state and systemic inflammatory response syndrome (SIRS).

Herndon, David N. "Pathophysiology of burn shock and burn edema" Total Burn Care. Fourth ed. Edinburgh: Saunders Elsevier, 2012. 110. Print.

What is the difference between Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN)?

antibiotics

Stevens-Johnson syndrome and toxic epidermal necrolysis are severe cutaneous hypersensitivity reactions. Drugs, especially sulfa drugs, antiepileptic’s, and antibiotics, are the most common causes. Macules rapidly spread and coalesce, leading to epidermal blistering, necrosis, and sloughing. Diagnosis is usually obvious by appearance of initial lesions and clinical syndrome. Treatment is supportive care; cyclosporine, plasma exchange or IVIG, and early pulse corticosteroid therapy have been used. Mortality can be as high as 7.5% in children and 20 to 25% in adults but tends to be lower with early treatment.

    SJS and TEN are clinically similar except for their distribution. By one commonly accepted definition, changes affect < 10% of body surface area in SJS and > 30% of body surface area in TEN; involvement of 15 to 30% of body surface area is considered SJS/TEN overlap.

    The disorders affect between 1 and 5 people/million. Incidence, severity, or both of these disorders may be higher in bone marrow transplant recipients, in Pneumocystis jirovecii–infected HIV patients, in patients with SLE, and in patients with other chronic rheumatologic diseases.


Rehmus, Wingfield E., MD. MPH. "Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) - Dermatologic Disorders." Merck Manuals Professional Edition. N.p., n.d. Web. 09 Mar. 2017.